A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07940803. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0662-3168 in Participants With Overweight or Obesity and Proof of Concept in Participants With Type 2 Diabetes.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn more about NNC0662-3168 as a potential treatment for people living with overweight or obesity and/or type 2 diabetes(T2D). The study will investigate its safety, tolerability and its effects in the body. The study will be conducted in four parts. Part A: Single Ascending Dose, Part B: Multiple Ascending Dose: Part C: Dose-finding in Weight Management. Part D: T2D proof-of-concept.
Study identification
- NCT ID
- NCT07940803
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Interventions
- NNC0662-3168 (Test product-A) Drug
- Placebo matched to NNC0662-3168 (Test product-A) Drug
- Active Comparator (Product-B) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2026 (Estimated)
- Primary completion
- Mar 25, 2028 (Estimated)
- Completion
- Mar 25, 2028 (Estimated)
- Last update posted
- Nov 17, 2026
2026 – 2028
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Celerion, Phoenix | Tempe | Arizona | 85283 | — |
| Celerion, Lincoln | Lincoln | Nebraska | 68502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07940803, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2026 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.